View Financial HealthCompumedics 배당 및 자사주 매입배당 기준 점검 0/6Compumedics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-4.9%자사주 매입 수익률총 주주 수익률-4.9%미래 배당 수익률16.8%배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공고 • Jun 09Compumedics Limited Announces Appointment of Mike Stone as Chief Commercial Officer for Its US OperationsCompumedics Limited announced appointment of Mike Stone as Chief Commercial Officer for its US operations. Mike brings over 20 years of medical device commercial leadership, with a proven record of scaling sales organizations, retaining key talent through M&A transitions, and integrating acquired businesses. Since joining, he has already strengthened the U.S. team with several high-caliber hires, with additional key appointments underway. Mike is charged with two strategic priorities: building out Compumedics' US neurodiagnostics business and strengthening the sleep and IDTF commercial teams to support continued growth, including Somfit, the company's EEG-enabled home sleep testing platform. Mike joins from Baxter International, where he led commercial operations spanning alternate site distribution and pharmaceutical manufacturing channels. Prior to Baxter, he served as Vice President of Sales at Smiths Medical, managing a $500 million plus P&L and holding the commercial organization together through its acquisition by ICU Medical. Earlier in his career, Mike led post-acquisition integration and team building across multiple transactions at Henry Schein, the Fortune 250 healthcare products and distribution leader. His tenure as Vice President of Sales for Neurology at Nihon Kohden gives him direct domain experience in EEG, sleep diagnostics, and software sales, where he transformed an underperforming business and drove strong double-digit growth sustained over multiple years. Mike holds an MBA from Georgia State University and a BS from the University of South Florida. He is based in Wellington, Florida.분석 기사 • Jan 29Compumedics Limited's (ASX:CMP) Price Is Right But Growth Is Lacking After Shares Rocket 26%The Compumedics Limited ( ASX:CMP ) share price has done very well over the last month, posting an excellent gain of...공고 • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.공고 • Oct 30Compumedics Limited Elects Mr. Christopher Barys as DirectorCompumedics Limited elected Mr. Christopher Barys as director.분석 기사 • Oct 16Compumedics Limited's (ASX:CMP) Price Is Right But Growth Is Lacking After Shares Rocket 29%The Compumedics Limited ( ASX:CMP ) share price has done very well over the last month, posting an excellent gain of...공고 • Oct 15Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,543,860 Price\Range: AUD 0.285 Discount Per Security: AUD 0.0171 Transaction Features: Subsequent Direct Listing분석 기사 • Oct 07Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt BurdenLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Reported Earnings • Oct 05Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 275% from FY 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.공고 • Oct 01Compumedics Limited, Annual General Meeting, Oct 30, 2025Compumedics Limited, Annual General Meeting, Oct 30, 2025. Location: 30-40 flockhart street, abbotsford victoria 3067, and via zoom meeting, AustraliaNew Risk • Aug 28New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risk Market cap is less than US$100m (AU$54.7m market cap, or US$35.6m).Reported Earnings • Aug 28Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 276% from FY 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.분석 기사 • Jul 28Even With A 25% Surge, Cautious Investors Are Not Rewarding Compumedics Limited's (ASX:CMP) Performance CompletelyCompumedics Limited ( ASX:CMP ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...분석 기사 • May 27Does Compumedics (ASX:CMP) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...분석 기사 • Mar 30Compumedics Limited (ASX:CMP) Held Back By Insufficient Growth Even After Shares Climb 29%Compumedics Limited ( ASX:CMP ) shareholders have had their patience rewarded with a 29% share price jump in the last...New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$61.5m market cap, or US$38.7m).Reported Earnings • Mar 04First half 2025 earnings releasedFirst half 2025 results: Revenue: AU$47.1m (up 78% from 1H 2024). Net loss: AU$2.23m (down AU$2.37m from profit in 1H 2024).분석 기사 • Feb 06Compumedics Limited's (ASX:CMP) Subdued P/S Might Signal An OpportunityWith a price-to-sales (or "P/S") ratio of 1x Compumedics Limited ( ASX:CMP ) may be sending very bullish signals at the...공고 • Dec 05Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,269,231 Price\Range: AUD 0.26 Discount Per Security: AUD 0.0156 Transaction Features: Subsequent Direct Listing분석 기사 • Oct 24This Is Why Compumedics Limited's (ASX:CMP) CEO Compensation Looks AppropriateKey Insights Compumedics to hold its Annual General Meeting on 31st of October CEO David Burton's total compensation...Reported Earnings • Oct 02Full year 2024 earnings released: AU$0.002 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.002 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.3m (up 17% from FY 2023). Net loss: AU$338.0k (loss narrowed 95% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.공고 • Oct 01Compumedics Limited, Annual General Meeting, Oct 31, 2024Compumedics Limited, Annual General Meeting, Oct 31, 2024. Location: 30-40 flockhart street, abbotsford victoria 3067 AustraliaReported Earnings • Aug 31Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.001 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.2m (up 17% from FY 2023). Net loss: AU$499.0k (loss narrowed 92% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.New Risk • Jul 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (AU$65.3m market cap, or US$44.1m).분석 기사 • Jun 17Further Upside For Compumedics Limited (ASX:CMP) Shares Could Introduce Price Risks After 38% BounceCompumedics Limited ( ASX:CMP ) shareholders would be excited to see that the share price has had a great month...New Risk • Jun 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (AU$51.4m market cap, or US$34.2m).분석 기사 • Mar 07Returns On Capital Signal Difficult Times Ahead For Compumedics (ASX:CMP)When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...New Risk • Nov 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 50% per year over the past 5 years. Minor Risk Market cap is less than US$100m (AU$34.5m market cap, or US$22.5m).분석 기사 • Nov 03We Think Compumedics (ASX:CMP) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...Reported Earnings • Oct 01Full year 2023 earnings released: AU$0.035 loss per share (vs AU$0.008 profit in FY 2022)Full year 2023 results: AU$0.035 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 11% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.공고 • Sep 28Compumedics Limited, Annual General Meeting, Oct 31, 2023Compumedics Limited, Annual General Meeting, Oct 31, 2023, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street, Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the Company and the reports of the Directors and the Company's auditor for the year ended 30 June 2023; to consider the election of Director; and to consider the adoption of Remuneration Report.Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.008 profit in FY 2022)Full year 2023 results: AU$0.004 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 14% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.공고 • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.분석 기사 • May 27Is Compumedics (ASX:CMP) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...공고 • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.Reported Earnings • Mar 03First half 2023 earnings released: AU$0.041 loss per share (vs AU$0.002 profit in 1H 2022)First half 2023 results: AU$0.041 loss per share (down from AU$0.002 profit in 1H 2022). Revenue: AU$19.2m (up 14% from 1H 2022). Net loss: AU$7.21m (down AU$7.50m from profit in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.분석 기사 • Jan 25Compumedics (ASX:CMP) Could Be At Risk Of Shrinking As A CompanyIf we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? A business...공고 • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.분석 기사 • Oct 19Some Shareholders May Object To A Pay Rise For Compumedics Limited's (ASX:CMP) CEO This YearThe disappointing performance at Compumedics Limited ( ASX:CMP ) will make some shareholders rather disheartened. At...분석 기사 • Oct 14Compumedics (ASX:CMP) Seems To Use Debt Quite SensiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Reported Earnings • Oct 01Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.공고 • Sep 29Compumedics Limited, Annual General Meeting, Oct 27, 2022Compumedics Limited, Annual General Meeting, Oct 27, 2022, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the company and the reports of the directors and the company's auditor for the year ended 30 June 2022; to consider the re-election of director; and to consider the adoption of remuneration report.Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.공고 • Aug 18Compumedics Limited Provides Revenue Guidance for the Fiscal Year 2023Compumedics Limited provided revenue guidance for the fiscal year 2023. For the period, Company expects revenues will be in excess of $40 million.분석 기사 • May 02Is Compumedics (ASX:CMP) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Mar 31Tucson Dunn Retires as Director of Compumedics Limited, Effective 31 March, 2022Compumedics Limited announced that Mr. Tucson Dunn, who was appointed a Director of the Company in May 2018, will retire as a Director of the Company, effective 31 March, 2022.Reported Earnings • Mar 03First half 2022 earnings: EPS and revenues miss analyst expectationsFirst half 2022 results: EPS: AU$0.002 (down from AU$0.007 in 1H 2021). Revenue: AU$16.8m (down 7.0% from 1H 2021). Net income: AU$287.0k (down 78% from 1H 2021). Profit margin: 1.7% (down from 7.3% in 1H 2021). Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) also missed analyst estimates by 33%. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.분석 기사 • Dec 08Compumedics (ASX:CMP) May Have Issues Allocating Its CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Reported Earnings • Oct 01Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$35.7m (up 1.9% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.8% (up from net loss in FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.Reported Earnings • Aug 27Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$37.3m (up 6.2% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.7% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance.분석 기사 • Aug 09Compumedics (ASX:CMP) Will Want To Turn Around Its Return TrendsWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...분석 기사 • Jun 10Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt BurdenSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...분석 기사 • May 06Returns On Capital Signal Tricky Times Ahead For Compumedics (ASX:CMP)To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...Is New 90 Day High Low • Mar 09New 90-day low: AU$0.41The company is down 16% from its price of AU$0.49 on 09 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 8.0% over the same period.분석 기사 • Feb 25These 4 Measures Indicate That Compumedics (ASX:CMP) Is Using Debt ExtensivelyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Reported Earnings • Feb 25First half 2021 earnings released: EPS AU$0.007 (vs AU$0.001 in 1H 2020)The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: AU$18.0m (down 1.4% from 1H 2020). Net income: AU$1.32m (up AU$1.16m from 1H 2020). Profit margin: 7.3% (up from 0.9% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 79% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.분석 기사 • Dec 01How Much Did Compumedics'(ASX:CMP) Shareholders Earn From Share Price Movements Over The Last Year?It is doubtless a positive to see that the Compumedics Limited (ASX:CMP) share price has gained some 32% in the last...Price Target Changed • Dec 01Price target lowered to AU$1.00Down from AU$1.15, the current price target is an average from 2 analysts. The new target price is 92% above the current share price of AU$0.52. As of last close, the stock is down 38% over the past year.공고 • Sep 07Compumedics Limited Announces Not to Provide Guidance for the Fiscal Year 2021Compumedics Limited announced that the ongoing and uncertain impacts of the COVID-19 Pandemic on key markets around the world make it very difficult to forecast the Company's expected results, for any given future period. As such, the Company remains unable to provide guidance at this time for the fiscal year 2021.공고 • Jul 17Compumedics Limited Announces That Sales Forecasts Will Remain Problematic Due to COVID-19 PandemicCompumedics Limited announced that initial sales pipelines for 2021 consistent with same time last year, with good new sales orders in the first weeks of 2021. Sales forecasts will remain problematic due to COVID-19 pandemic.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 CMP 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: CMP 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Compumedics 배당 수익률 vs 시장CMP의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (CMP)n/a시장 하위 25% (AU)2.7%시장 상위 25% (AU)6.6%업계 평균 (Medical Equipment)2.1%분석가 예측 (CMP) (최대 3년)16.8%주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 CMP 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 CMP 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 CMP 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: CMP 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YAU 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/18 19:04종가2026/07/17 00:00수익2025/12/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Compumedics Limited는 3명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Ian MartinNew Street Research LLPPaul JenszPAC Partners Securities Pty. Ltd.Stephen ScottTaylor Collison Limited
공고 • Jun 09Compumedics Limited Announces Appointment of Mike Stone as Chief Commercial Officer for Its US OperationsCompumedics Limited announced appointment of Mike Stone as Chief Commercial Officer for its US operations. Mike brings over 20 years of medical device commercial leadership, with a proven record of scaling sales organizations, retaining key talent through M&A transitions, and integrating acquired businesses. Since joining, he has already strengthened the U.S. team with several high-caliber hires, with additional key appointments underway. Mike is charged with two strategic priorities: building out Compumedics' US neurodiagnostics business and strengthening the sleep and IDTF commercial teams to support continued growth, including Somfit, the company's EEG-enabled home sleep testing platform. Mike joins from Baxter International, where he led commercial operations spanning alternate site distribution and pharmaceutical manufacturing channels. Prior to Baxter, he served as Vice President of Sales at Smiths Medical, managing a $500 million plus P&L and holding the commercial organization together through its acquisition by ICU Medical. Earlier in his career, Mike led post-acquisition integration and team building across multiple transactions at Henry Schein, the Fortune 250 healthcare products and distribution leader. His tenure as Vice President of Sales for Neurology at Nihon Kohden gives him direct domain experience in EEG, sleep diagnostics, and software sales, where he transformed an underperforming business and drove strong double-digit growth sustained over multiple years. Mike holds an MBA from Georgia State University and a BS from the University of South Florida. He is based in Wellington, Florida.
분석 기사 • Jan 29Compumedics Limited's (ASX:CMP) Price Is Right But Growth Is Lacking After Shares Rocket 26%The Compumedics Limited ( ASX:CMP ) share price has done very well over the last month, posting an excellent gain of...
공고 • Jan 22+ 1 more updateCompumedics Limited Provides Earnings Guidance for the Fiscal Year 2026Compumedics Limited provided earnings guidance for the fiscal year 2026. For the year, company expected Revenue to be: $70 million.
공고 • Oct 30Compumedics Limited Elects Mr. Christopher Barys as DirectorCompumedics Limited elected Mr. Christopher Barys as director.
분석 기사 • Oct 16Compumedics Limited's (ASX:CMP) Price Is Right But Growth Is Lacking After Shares Rocket 29%The Compumedics Limited ( ASX:CMP ) share price has done very well over the last month, posting an excellent gain of...
공고 • Oct 15Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 7,543,860 Price\Range: AUD 0.285 Discount Per Security: AUD 0.0171 Transaction Features: Subsequent Direct Listing
분석 기사 • Oct 07Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt BurdenLegendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Reported Earnings • Oct 05Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 275% from FY 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 19% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has only increased by 6% per year, which means it is significantly lagging earnings growth.
공고 • Oct 01Compumedics Limited, Annual General Meeting, Oct 30, 2025Compumedics Limited, Annual General Meeting, Oct 30, 2025. Location: 30-40 flockhart street, abbotsford victoria 3067, and via zoom meeting, Australia
New Risk • Aug 28New major risk - Financial positionThe company's interest payments are not well covered by earnings. Net interest cover: 0.6x This is considered a major risk. If the company is unable to fund interest repayments on its debt through profits, it may be forced into reducing its debt burden through selling assets, undertaking a potentially costly capital raising or even into bankruptcy in the worst case scenario. Currently, the following risks have been identified for the company: Major Risk Interest payments are not well covered by earnings (0.6x net interest cover). Minor Risk Market cap is less than US$100m (AU$54.7m market cap, or US$35.6m).
Reported Earnings • Aug 28Full year 2025 earnings: EPS and revenues miss analyst expectationsFull year 2025 results: AU$0.007 loss per share (further deteriorated from AU$0.002 loss in FY 2024). Revenue: AU$51.0m (up 1.5% from FY 2024). Net loss: AU$1.27m (loss widened 276% from FY 2024). Revenue missed analyst estimates by 10%. Earnings per share (EPS) were also behind analyst expectations. Revenue is forecast to grow 13% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia. Over the last 3 years on average, earnings per share has increased by 33% per year but the company’s share price has fallen by 1% per year, which means it is significantly lagging earnings.
분석 기사 • Jul 28Even With A 25% Surge, Cautious Investors Are Not Rewarding Compumedics Limited's (ASX:CMP) Performance CompletelyCompumedics Limited ( ASX:CMP ) shares have had a really impressive month, gaining 25% after a shaky period beforehand...
분석 기사 • May 27Does Compumedics (ASX:CMP) Have A Healthy Balance Sheet?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
분석 기사 • Mar 30Compumedics Limited (ASX:CMP) Held Back By Insufficient Growth Even After Shares Climb 29%Compumedics Limited ( ASX:CMP ) shareholders have had their patience rewarded with a 29% share price jump in the last...
New Risk • Mar 21New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 13% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Market cap is less than US$100m (AU$61.5m market cap, or US$38.7m).
Reported Earnings • Mar 04First half 2025 earnings releasedFirst half 2025 results: Revenue: AU$47.1m (up 78% from 1H 2024). Net loss: AU$2.23m (down AU$2.37m from profit in 1H 2024).
분석 기사 • Feb 06Compumedics Limited's (ASX:CMP) Subdued P/S Might Signal An OpportunityWith a price-to-sales (or "P/S") ratio of 1x Compumedics Limited ( ASX:CMP ) may be sending very bullish signals at the...
공고 • Dec 05Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million.Compumedics Limited has completed a Follow-on Equity Offering in the amount of AUD 2.15 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 8,269,231 Price\Range: AUD 0.26 Discount Per Security: AUD 0.0156 Transaction Features: Subsequent Direct Listing
분석 기사 • Oct 24This Is Why Compumedics Limited's (ASX:CMP) CEO Compensation Looks AppropriateKey Insights Compumedics to hold its Annual General Meeting on 31st of October CEO David Burton's total compensation...
Reported Earnings • Oct 02Full year 2024 earnings released: AU$0.002 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.002 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.3m (up 17% from FY 2023). Net loss: AU$338.0k (loss narrowed 95% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 31% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
공고 • Oct 01Compumedics Limited, Annual General Meeting, Oct 31, 2024Compumedics Limited, Annual General Meeting, Oct 31, 2024. Location: 30-40 flockhart street, abbotsford victoria 3067 Australia
Reported Earnings • Aug 31Full year 2024 earnings released: AU$0.001 loss per share (vs AU$0.035 loss in FY 2023)Full year 2024 results: AU$0.001 loss per share (improved from AU$0.035 loss in FY 2023). Revenue: AU$50.2m (up 17% from FY 2023). Net loss: AU$499.0k (loss narrowed 92% from FY 2023). Over the last 3 years on average, earnings per share has fallen by 32% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
New Risk • Jul 07New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.8% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (13% average weekly change). Large one-off items impacting financial results. Shareholders have been diluted in the past year (3.8% increase in shares outstanding). Market cap is less than US$100m (AU$65.3m market cap, or US$44.1m).
분석 기사 • Jun 17Further Upside For Compumedics Limited (ASX:CMP) Shares Could Introduce Price Risks After 38% BounceCompumedics Limited ( ASX:CMP ) shareholders would be excited to see that the share price has had a great month...
New Risk • Jun 08New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 38% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (AU$51.4m market cap, or US$34.2m).
분석 기사 • Mar 07Returns On Capital Signal Difficult Times Ahead For Compumedics (ASX:CMP)When it comes to investing, there are some useful financial metrics that can warn us when a business is potentially in...
New Risk • Nov 17New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Australian stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 50% per year over the past 5 years. Minor Risk Market cap is less than US$100m (AU$34.5m market cap, or US$22.5m).
분석 기사 • Nov 03We Think Compumedics (ASX:CMP) Has A Fair Chunk Of DebtWarren Buffett famously said, 'Volatility is far from synonymous with risk.' So it seems the smart money knows that...
Reported Earnings • Oct 01Full year 2023 earnings released: AU$0.035 loss per share (vs AU$0.008 profit in FY 2022)Full year 2023 results: AU$0.035 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 11% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has fallen by 8% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
공고 • Sep 28Compumedics Limited, Annual General Meeting, Oct 31, 2023Compumedics Limited, Annual General Meeting, Oct 31, 2023, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street, Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the Company and the reports of the Directors and the Company's auditor for the year ended 30 June 2023; to consider the election of Director; and to consider the adoption of Remuneration Report.
Reported Earnings • Aug 31Full year 2023 earnings released: AU$0.004 loss per share (vs AU$0.008 profit in FY 2022)Full year 2023 results: AU$0.004 loss per share (down from AU$0.008 profit in FY 2022). Revenue: AU$42.9m (up 14% from FY 2022). Net loss: AU$6.12m (down AU$7.48m from profit in FY 2022). Over the last 3 years on average, earnings per share has increased by 41% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
공고 • Jul 06Compumedics Limited Provides Revenue Guidance for the Year 2023Compumedics Limited provided revenue guidance for the year 2023. For the year, the company expects Revenues are expected to be about $41 million.
분석 기사 • May 27Is Compumedics (ASX:CMP) A Risky Investment?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
공고 • May 06Compumedics Limited Re-Affirms Earnings Guidance for the Fiscal Year 2023Compumedics Limited re-affirmed earnings guidance for the fiscal year 2023. For the year, the company expects revenue to be more than $40 million.
Reported Earnings • Mar 03First half 2023 earnings released: AU$0.041 loss per share (vs AU$0.002 profit in 1H 2022)First half 2023 results: AU$0.041 loss per share (down from AU$0.002 profit in 1H 2022). Revenue: AU$19.2m (up 14% from 1H 2022). Net loss: AU$7.21m (down AU$7.50m from profit in 1H 2022). Over the last 3 years on average, earnings per share has fallen by 2% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
분석 기사 • Jan 25Compumedics (ASX:CMP) Could Be At Risk Of Shrinking As A CompanyIf we're looking to avoid a business that is in decline, what are the trends that can warn us ahead of time? A business...
공고 • Jan 25+ 1 more updateCompumedics Limited Provides Revenue Guidance for the First Half of Fiscal Year 2023Compumedics Limited provided revenue guidance for the first half of fiscal year 2023. The company expects revenues to be about 7% higher at $18.0 million for first half of fiscal year 2023, compared to first half fiscal year 2022.
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
분석 기사 • Oct 19Some Shareholders May Object To A Pay Rise For Compumedics Limited's (ASX:CMP) CEO This YearThe disappointing performance at Compumedics Limited ( ASX:CMP ) will make some shareholders rather disheartened. At...
분석 기사 • Oct 14Compumedics (ASX:CMP) Seems To Use Debt Quite SensiblyDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Reported Earnings • Oct 01Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 26% per year, which means it is performing significantly worse than earnings.
공고 • Sep 29Compumedics Limited, Annual General Meeting, Oct 27, 2022Compumedics Limited, Annual General Meeting, Oct 27, 2022, at 10:30 AUS Eastern Standard Time. Location: 30-40 Flockhart Street Abbotsford Victoria Australia Agenda: To receive and consider the financial report of the company and the reports of the directors and the company's auditor for the year ended 30 June 2022; to consider the re-election of director; and to consider the adoption of remuneration report.
Reported Earnings • Aug 19Full year 2022 earnings released: EPS: AU$0.008 (vs AU$0.006 in FY 2021)Full year 2022 results: EPS: AU$0.008 (up from AU$0.006 in FY 2021). Revenue: AU$37.8m (up 5.6% from FY 2021). Net income: AU$1.36m (up 36% from FY 2021). Profit margin: 3.6% (up from 2.8% in FY 2021). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 19% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
공고 • Aug 18Compumedics Limited Provides Revenue Guidance for the Fiscal Year 2023Compumedics Limited provided revenue guidance for the fiscal year 2023. For the period, Company expects revenues will be in excess of $40 million.
분석 기사 • May 02Is Compumedics (ASX:CMP) Using Debt Sensibly?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Non-Executive Director Paul Jensz was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Mar 31Tucson Dunn Retires as Director of Compumedics Limited, Effective 31 March, 2022Compumedics Limited announced that Mr. Tucson Dunn, who was appointed a Director of the Company in May 2018, will retire as a Director of the Company, effective 31 March, 2022.
Reported Earnings • Mar 03First half 2022 earnings: EPS and revenues miss analyst expectationsFirst half 2022 results: EPS: AU$0.002 (down from AU$0.007 in 1H 2021). Revenue: AU$16.8m (down 7.0% from 1H 2021). Net income: AU$287.0k (down 78% from 1H 2021). Profit margin: 1.7% (down from 7.3% in 1H 2021). Revenue missed analyst estimates by 4.4%. Earnings per share (EPS) also missed analyst estimates by 33%. Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.
분석 기사 • Dec 08Compumedics (ASX:CMP) May Have Issues Allocating Its CapitalIf we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...
Reported Earnings • Oct 01Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$35.7m (up 1.9% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.8% (up from net loss in FY 2020). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 72 percentage points per year, which is a significant difference in performance.
Reported Earnings • Aug 27Full year 2021 earnings released: EPS AU$0.006 (vs AU$0.033 loss in FY 2020)The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$37.3m (up 6.2% from FY 2020). Net income: AU$998.0k (up AU$6.84m from FY 2020). Profit margin: 2.7% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 68 percentage points per year, which is a significant difference in performance.
분석 기사 • Aug 09Compumedics (ASX:CMP) Will Want To Turn Around Its Return TrendsWhat are the early trends we should look for to identify a stock that could multiply in value over the long term...
분석 기사 • Jun 10Here's Why Compumedics (ASX:CMP) Has A Meaningful Debt BurdenSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
분석 기사 • May 06Returns On Capital Signal Tricky Times Ahead For Compumedics (ASX:CMP)To find a multi-bagger stock, what are the underlying trends we should look for in a business? Ideally, a business will...
Is New 90 Day High Low • Mar 09New 90-day low: AU$0.41The company is down 16% from its price of AU$0.49 on 09 December 2020. The Australian market is up 1.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Medical Equipment industry, which is down 8.0% over the same period.
분석 기사 • Feb 25These 4 Measures Indicate That Compumedics (ASX:CMP) Is Using Debt ExtensivelyThe external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Reported Earnings • Feb 25First half 2021 earnings released: EPS AU$0.007 (vs AU$0.001 in 1H 2020)The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: AU$18.0m (down 1.4% from 1H 2020). Net income: AU$1.32m (up AU$1.16m from 1H 2020). Profit margin: 7.3% (up from 0.9% in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 79% per year but the company’s share price has increased by 7% per year, which means it is well ahead of earnings.
분석 기사 • Dec 01How Much Did Compumedics'(ASX:CMP) Shareholders Earn From Share Price Movements Over The Last Year?It is doubtless a positive to see that the Compumedics Limited (ASX:CMP) share price has gained some 32% in the last...
Price Target Changed • Dec 01Price target lowered to AU$1.00Down from AU$1.15, the current price target is an average from 2 analysts. The new target price is 92% above the current share price of AU$0.52. As of last close, the stock is down 38% over the past year.
공고 • Sep 07Compumedics Limited Announces Not to Provide Guidance for the Fiscal Year 2021Compumedics Limited announced that the ongoing and uncertain impacts of the COVID-19 Pandemic on key markets around the world make it very difficult to forecast the Company's expected results, for any given future period. As such, the Company remains unable to provide guidance at this time for the fiscal year 2021.
공고 • Jul 17Compumedics Limited Announces That Sales Forecasts Will Remain Problematic Due to COVID-19 PandemicCompumedics Limited announced that initial sales pipelines for 2021 consistent with same time last year, with good new sales orders in the first weeks of 2021. Sales forecasts will remain problematic due to COVID-19 pandemic.